|
|
|
|
| Mikart’s 50 years of experience as a CDMO in oral solid and nonsterile oral liquid dosage forms, combined with our specialization in pediatric, geriatric, and controlled-substance products, make us an ideal partner from formulation development through commercialization. We prioritize long-lasting relationships and a personalized, hands-on approach — delivering the reliability, technical expertise, and flexibility needed to meet your goals, navigate complexity, and consistently exceed expectations at every stage. Click here to learn more. |
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Chief Editor Louis Garguilo warns against letting lengthy checklists overshadow core needs when selecting a CDMO. Learn how focusing on fundamentals can lead to better partner decisions. | |
|
|
|
By Juergen M. Metzger, Pharma-Technology-Consulting, LLC | Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. RABS are frequently dismissed too quickly. The difference is not the technology itself, but how it is applied. | |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| Key Innovations Shaping Inhaled Biologics | Article | Experic | Inhaled biologics are advancing as better formulations, particle design, and devices enable targeted delivery. Tracking key trends helps teams manage complexity and advance future therapies. |
|
|
|
| Rare Diseases And The Integrated CDMO Support System | Article | By David O’Connell, PCI Pharma Services | Champion the rare‑disease community by advancing development models built on precision, continuity and global coordination that ensure every dose reaches the patients who need it most. |
|
|
| Integrated CNS Drug Development Solutions | E-Book | Altasciences | Understand how early engagement with a fully integrated and experienced CNS drug development partner can accelerate timelines by facilitating continuous data sharing and decision-making. |
|
|
|
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
